S2 Ep25: Representation, Education, and Revolutionizing Sunscreen for Skin of Color

S2 Ep26: New ICD-10 Code Offers Validation for Patients With Topical Steroid Withdrawal

In the most recent episode of the Derm Dispatch video series [https://www.dermatologytimes.com/podcasts/derm-dispatch], host Renata Block, DMSCc, MMS, PA-C, a Chicago-based physician assistant, interviewed Kelly Barta, the president and executive director of the International Topical Steroid Awareness Network (ITSAN) [https://www.itsan.org/], to discuss the new ICD-10 code for topical steroid withdrawal and ITSAN's patient registry.  The ICD-10 code for TSW went through 3 formal reviews with the CDC and a split board vote before receiving final approval, with support from the American Academy of Dermatology. Barta said the designation gives patients a formal diagnosis within the health system for the first time and allows researchers to begin capturing incidence and prevalence data.

S2 Ep25: Representation, Education, and Revolutionizing Sunscreen for Skin of Color

In this episode, we spoke with Shontay Lundy, founder and CEO of Black Girl Sunscreen, about the inspiration behind building a sunscreen brand designed for people with melanin-rich skin and the broader challenges surrounding sun protection in skin of color. In our discussion, Lundy reflected on gaps in education, representation, product development, and clinical research, while sharing her perspective on how dermatologists, estheticians, brands, and industry leaders can work together to improve sunscreen adoption and skin health outcomes across diverse patient populations.

S2 Ep24: Debunking Allergy Myths and the Future of Atopic Dermatitis Treatment

In this episode of The Cutaneous Connection, Dermatology Times revisits a recent video episode of the Derm Dispatch show where host Renata Block, DMSc, MMS, PA-C, sits down with Zachary Rubin, MD — allergist, pediatrician, and New York Times bestselling author of All About Allergies — to explore the intersection of dermatology and allergy. Together, they tackle one of the most persistent myths in practice: that food elimination can treat atopic dermatitis. Dr. Rubin breaks down the difference between IgE-mediated allergic reactions and the complex inflammatory nature of eczema, explains the atopic march, and discusses how understanding the gut-lung-skin axis can empower patients to take charge of their care. The conversation also covers the latest treatment advances — from JAK inhibitors to novel biologics — and touches on indolent systemic mastocytosis and the truth about so-called hypoallergenic dogs. A must-listen for any clinician treating allergic and inflammatory skin disease. For more content, visit https://www.dermatologytimes.com/ [https://www.dermatologytimes.com/]

S2 Ep23: Diving Into the Safety and Efficacy of Icotrokinra, the New Oral IL-23 Peptide in Psoriasis

Join Dermatology Times for a conversation with Liza O'Dowd, MD, vice president of immunodermatology and respiratory disease areas at Johnson & Johnson, recorded at the 2026 AAD Annual Meeting. Dr. O'Dowd discusses one-year efficacy and safety data for icotrokinra (Icotyde), the newly approved once-daily oral peptide IL-23 receptor antagonist for moderate to severe plaque psoriasis in adults and adolescents 12 and older. At 52 weeks, approximately 50% of adult patients achieved total skin clearance, rising to 60% in adolescents enrolled in the LEAD study. Adverse event rates through one year remained within 1.1% of placebo, with no mandatory tuberculosis pre-screening required. Dr. O'Dowd also addresses icotrokinra's anticipated role as a first-line systemic therapy and offers practical reassurance for clinicians considering this novel agent for their patients. For more content from Dermatology Times, visit https://www.dermatologytimes.com/ [https://www.dermatologytimes.com/]

S2 Ep22: Can GLP-1 Therapy Revolutionize Chronic Skin Treatment?

In this episode, board-certified dermatologist of US Dermatology Partners, Daniel Walker, MD, FAAD, shares emerging insights into the expanding role of GLP-1 receptor agonists beyond their primary use in diabetes and weight loss, highlighting their promising—yet still investigational—impact on inflammatory skin diseases such as psoriasis and HS.